Clinical properties of patients with CLL
| Patient no.* . | Sex . | Rai stage† . | Age, y . | WBC, × 106/mL . | Disease duration, y . | Treatment‡ . | CD38, % . | Cytogenetics§ . |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 4 | 56 | 122 | 7 | C/P, FCR | 10 | 13q− |
| 2 | F | 2 | 57 | 42 | 11 | C/P | 8 | 13q− |
| 6 | M | 0 | 63 | 27 | 5 | None | 9 | Normal |
| 7 | F | 0 | 44 | 24 | 6 | None | 4 | Normal |
| 9 | M | 0 | 69 | 34 | 9 | None | 5 | Normal |
| 13 | F | 4 | 34 | 55 | 11 | C/P, FCR | 25 | T12 |
| 22 | M | 2 | 58 | 52 | 6 | C/P, FC, BMT | 45 | 11q− |
| 23 | M | 2 | 70 | 125 | 12 | CVP, S,FC (three ×) | 2 | 11q− |
| 25 | F | 3 | 60 | 87 | 11 | S, CP | 1 | 13q− |
| 27 | F | 3 | 80 | 122 | 10 | P | 8 | T12 |
| 28 | M | 4 | 64 | 77 | 8 | S, CP | NA | 13q− |
| 30 | F | 3 | 70 | 142 | 4 | C | 3 | T12 |
| 31 | M | 4 | 59 | 59 | 10 | F, Rev, CHOP | 14 | 13q− |
| 44 | F | 4 | 54 | 65 | 17 | None | 2 | 13q− |
| 55 | M | 0 | 75 | 42 | 6 | C/P, S, FC | 40 | T12 |
| 56 | M | 3 | 55 | 142 | 11 | C/P, Rev | 22 | Normal |
| 57 | M | 3 | 47 | 33 | 6 | C/P, BMT | 8 | T12 |
| 71 | F | 4 | 74 | 120 | 2 | P | NA | 17p− |
| 73 | M | 0 | 85 | 42 | 3 | None | 1 | 17p− |
| 74 | M | 3 | 69 | 93 | 5 | C/P | 4 | 11q− |
| 78 | M | 2 | 71 | 122 | 5 | C/P, S, FCR | 13 | normal |
| 81 | F | 3 | 50 | 22 | 6 | S | 7 | 17p− |
| 82 | M | 4 | 86 | 43 | 5 | CVP, FC, Rads | 71 | 11q− |
| 83 | M | 2 | 49 | 63 | 3 | C/P, FC, BMT | 30 | 11q− |
| 86 | M | 2 | 58 | 65 | 6 | C, FC, Rev | 3 | 13q− |
| 89 | M | 4 | 75 | 72 | 8 | F, R, P, S | NA | 17p− |
| 92 | M | 4 | 56 | 42 | 6 | CHOP, P, R | 81 | 17p− |
| 93 | M | 3 | 62 | 70 | 2 | Rev | NA | 11q− |
| 95 | F | 4 | 60 | 80 | 8 | C/P, FC, FCR | 2 | T12 |
| 96 | M | 2 | 54 | 71 | 6 | C/P | 15 | Normal |
| 105 | F | 3 | 68 | 153 | 9 | Ch, FC | NA | Normal |
| 106 | F | 3 | 69 | 229 | 7 | C/P, FC | 1 | 13q− |
| 109 | F | 3 | 64 | 139 | 7 | C/P, FCR | 51 | Normal |
| 110 | F | 3 | 62 | 98 | 7 | C/P | 20 | T12 |
| 111 | F | 0 | 74 | 54 | 4 | None | 4 | 17p− |
| 114 | M | 4 | 54 | 14 | 11 | C/P, F, CHOP, Rev | 38 | Normal |
| 115 | M | 4 | 57 | 100 | 9 | C/P, FC, S, CHOPR | 54 | 17p− |
| 116 | M | 4 | 55 | 120 | 14 | C, CVP, FC | 1 | Normal |
| 119 | M | 2 | 74 | 42 | 5 | None | 2 | 11q− |
| 120 | M | 4 | 72 | 200 | 6 | C/P, S, CHOP | NA | 17p− |
| 176 | F | 3 | 74 | 17 | 5 | C, CP | 43 | T12 |
| 141 | F | 4 | 62 | 520 | 27 | S | 18 | 11q− |
| 175 | M | 4 | 75 | 183 | 6 | P | 25 | 13q− |
| 134 | M | 3 | 80 | 5 | 7 | C/P, S | NA | 13q− |
| 158 | M | 3 | 56 | 126 | 5 | C/P/R, S | 14 | T12 |
| 132 | M | 2 | 58 | 134 | 3 | None | 1 | T12 |
| 125 | F | 3 | 65 | 76 | 4 | None | NA | T12 |
| Patient no.* . | Sex . | Rai stage† . | Age, y . | WBC, × 106/mL . | Disease duration, y . | Treatment‡ . | CD38, % . | Cytogenetics§ . |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 4 | 56 | 122 | 7 | C/P, FCR | 10 | 13q− |
| 2 | F | 2 | 57 | 42 | 11 | C/P | 8 | 13q− |
| 6 | M | 0 | 63 | 27 | 5 | None | 9 | Normal |
| 7 | F | 0 | 44 | 24 | 6 | None | 4 | Normal |
| 9 | M | 0 | 69 | 34 | 9 | None | 5 | Normal |
| 13 | F | 4 | 34 | 55 | 11 | C/P, FCR | 25 | T12 |
| 22 | M | 2 | 58 | 52 | 6 | C/P, FC, BMT | 45 | 11q− |
| 23 | M | 2 | 70 | 125 | 12 | CVP, S,FC (three ×) | 2 | 11q− |
| 25 | F | 3 | 60 | 87 | 11 | S, CP | 1 | 13q− |
| 27 | F | 3 | 80 | 122 | 10 | P | 8 | T12 |
| 28 | M | 4 | 64 | 77 | 8 | S, CP | NA | 13q− |
| 30 | F | 3 | 70 | 142 | 4 | C | 3 | T12 |
| 31 | M | 4 | 59 | 59 | 10 | F, Rev, CHOP | 14 | 13q− |
| 44 | F | 4 | 54 | 65 | 17 | None | 2 | 13q− |
| 55 | M | 0 | 75 | 42 | 6 | C/P, S, FC | 40 | T12 |
| 56 | M | 3 | 55 | 142 | 11 | C/P, Rev | 22 | Normal |
| 57 | M | 3 | 47 | 33 | 6 | C/P, BMT | 8 | T12 |
| 71 | F | 4 | 74 | 120 | 2 | P | NA | 17p− |
| 73 | M | 0 | 85 | 42 | 3 | None | 1 | 17p− |
| 74 | M | 3 | 69 | 93 | 5 | C/P | 4 | 11q− |
| 78 | M | 2 | 71 | 122 | 5 | C/P, S, FCR | 13 | normal |
| 81 | F | 3 | 50 | 22 | 6 | S | 7 | 17p− |
| 82 | M | 4 | 86 | 43 | 5 | CVP, FC, Rads | 71 | 11q− |
| 83 | M | 2 | 49 | 63 | 3 | C/P, FC, BMT | 30 | 11q− |
| 86 | M | 2 | 58 | 65 | 6 | C, FC, Rev | 3 | 13q− |
| 89 | M | 4 | 75 | 72 | 8 | F, R, P, S | NA | 17p− |
| 92 | M | 4 | 56 | 42 | 6 | CHOP, P, R | 81 | 17p− |
| 93 | M | 3 | 62 | 70 | 2 | Rev | NA | 11q− |
| 95 | F | 4 | 60 | 80 | 8 | C/P, FC, FCR | 2 | T12 |
| 96 | M | 2 | 54 | 71 | 6 | C/P | 15 | Normal |
| 105 | F | 3 | 68 | 153 | 9 | Ch, FC | NA | Normal |
| 106 | F | 3 | 69 | 229 | 7 | C/P, FC | 1 | 13q− |
| 109 | F | 3 | 64 | 139 | 7 | C/P, FCR | 51 | Normal |
| 110 | F | 3 | 62 | 98 | 7 | C/P | 20 | T12 |
| 111 | F | 0 | 74 | 54 | 4 | None | 4 | 17p− |
| 114 | M | 4 | 54 | 14 | 11 | C/P, F, CHOP, Rev | 38 | Normal |
| 115 | M | 4 | 57 | 100 | 9 | C/P, FC, S, CHOPR | 54 | 17p− |
| 116 | M | 4 | 55 | 120 | 14 | C, CVP, FC | 1 | Normal |
| 119 | M | 2 | 74 | 42 | 5 | None | 2 | 11q− |
| 120 | M | 4 | 72 | 200 | 6 | C/P, S, CHOP | NA | 17p− |
| 176 | F | 3 | 74 | 17 | 5 | C, CP | 43 | T12 |
| 141 | F | 4 | 62 | 520 | 27 | S | 18 | 11q− |
| 175 | M | 4 | 75 | 183 | 6 | P | 25 | 13q− |
| 134 | M | 3 | 80 | 5 | 7 | C/P, S | NA | 13q− |
| 158 | M | 3 | 56 | 126 | 5 | C/P/R, S | 14 | T12 |
| 132 | M | 2 | 58 | 134 | 3 | None | 1 | T12 |
| 125 | F | 3 | 65 | 76 | 4 | None | NA | T12 |
NA indicates not available; and WBC, white blood cell.
Corresponding patient numbers are maintained throughout.
Rai stage classification: 0 = lymphocytosis; 1 = with adenopathy; 2 = with hepatosplenomegaly; 3 = with anemia; 4 = with thrombocytopenia.11
Treatment by C indicates chlorambucil; P, prednisone; F, fludarabine; S, splenectomy; Rads, local radiation; R, rituxan; CHOP, cyclophosphamide/vincristine/adriamycin/prednisone; FC, fludarabine/cyclophosphamide; CVP, cyclophosphamide/vincristine/prednisone; BMT, allogeneic bone marrow transplantation; and Rev, revlimid.
In the case of multiple cytogenetic lesions, data for the higher risk lesion were used (eg, 11q− or 17p−)